<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1920">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796402</url>
  </required_header>
  <id_info>
    <org_study_id>FHREB 2021-023</org_study_id>
    <nct_id>NCT04796402</nct_id>
  </id_info>
  <brief_title>A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19</brief_title>
  <acronym>B-EPIC</acronym>
  <official_title>A Pragmatic Eight Week Phase IV Study of Bamlanivimab/LY-CoV555 for Emergency Passive Immunity Against COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fraser Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fraser Health Authrority Department of Evaluation and Research Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Surrey Memorial Hospital Clinical Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Health Evaluation and Outcome Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Surrey Hospital Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BC Support Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Trials BC (part of the BC Academic Health Science Network)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fraser Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to test whether a new medication called bamlanivimab is safe&#xD;
      and effective at reducing the need for hospitalization due to COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to examine the effectiveness of adding bamlanivimab provided by COVID-19&#xD;
      Clinics to standard of care on the incidence of hospitalization for high-risk patients&#xD;
      infected with SARS-CoV2. Furthermore, we aim to test the effect on the following secondary&#xD;
      outcomes: mortality and health-related quality of life and patients' satisfaction with care.&#xD;
      We will also assess the recruitment rate from the three primary strategies for rapid&#xD;
      identification and consent of eligible patients. The data from this study will inform&#xD;
      clinical decisions about the use of bamlanivimab in high risk COVID-19 patients and the&#xD;
      operational requirements necessary for research in passive immunity therapeutics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 17, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any incidence of admission to hospital for &gt;24 hours in the 28 days following first positive test for SARS-CoV2.</measure>
    <time_frame>0 - 28 days following first positive test for COVID 19</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Any incidence of admission to hospital for &gt;24 hours following first positive test for SARS-CoV2.</measure>
    <time_frame>0 - 28 days following first positive test for COVID-19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality following first positive test for SARS-CoV2.</measure>
    <time_frame>28 days, 3 month and 6 months post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life assessment.</measure>
    <time_frame>Screening and 6 months post-treatment</time_frame>
    <description>Medical Outcomes Study: 20-Item Short Form Survey Instrument (SF-20)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization by age and comorbidities.</measure>
    <time_frame>Treatment day and up to 6 months post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and types of adverse reactions including anaphylaxis.</measure>
    <time_frame>Treatment day and up to 6 months post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recruitment rate.</measure>
    <time_frame>Upto 8 weeks from day of first patient recruited to day of last patient recruited</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall satisfaction with participation in research.</measure>
    <time_frame>6 months post-treatment</time_frame>
    <description>Likert Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type and frequency of viral variants in patients receiving bamlanivimab.</measure>
    <time_frame>Up to 8 weeks from day of first patient recruited to day of last patient recruited</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">576</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Bamlanivimab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bamlanivimab</intervention_name>
    <description>700 mg/20mL IV over at least one hour OD</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of care includes primary care and specialist care as indicated by the patient's primary care provider</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age at the time of SARS-CoV2 test:&#xD;
&#xD;
               1. Age &gt; 65&#xD;
&#xD;
               2. Age 55-64 and 1 or more of:&#xD;
&#xD;
             i. BMI&gt;35, ii. chronic kidney disease, iii. diabetes mellitus, iv. immunosuppressive&#xD;
             disease v. current immunosuppressive treatment vi. hypertension vii. coronary artery&#xD;
             disease viii. chronic lung disease&#xD;
&#xD;
             c. Age 18-54 and 1 or more of: i. BMI&gt;35 ii. chronic kidney disease iii. diabetes&#xD;
             mellitus iv. immunosuppressive disease v. current immunosuppressive treatment&#xD;
&#xD;
          2. Disease Characteristics:&#xD;
&#xD;
               1. Not hospitalized&#xD;
&#xD;
               2. Sample collection for first SARS-CoV2 test positive within 3 days prior to&#xD;
                  consent.&#xD;
&#xD;
               3. One or more mild COVID-19 symptoms and within 10 days from onset&#xD;
&#xD;
             i. Fever ii. Cough iii. Sore throat iv. Malaise v. Headache vi. Muscle pain vii.&#xD;
             Gastrointestinal symptoms viii. Shortness of breath with/without exertion&#xD;
&#xD;
          3. Study Procedures:&#xD;
&#xD;
               1. Resident of British Columbia&#xD;
&#xD;
               2. Understand and agree to planned study procedures&#xD;
&#xD;
          4. Ability and Willingness to Provide Informed Consent:&#xD;
&#xD;
        The participant will provide informed consent by telephone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical Conditions&#xD;
&#xD;
               1. Allergies to any of the components used in the formulation of the bamlanivimab&#xD;
&#xD;
               2. Hospitalization or expected to need hospitalization in the next 24 hours at the&#xD;
                  time of recruitment for COVID-19&#xD;
&#xD;
               3. Suspected or proven infection other than COVID-19 that in the opinion of the&#xD;
                  clinicians could pose a risk to study inclusion&#xD;
&#xD;
               4. Any co-morbidity considered life-threatening in &lt;28 days, or requiring surgery in&#xD;
                  &lt;7 days.&#xD;
&#xD;
               5. Any serious disease, condition or disorder that in the opinion of the clinicians&#xD;
                  should preclude participation.&#xD;
&#xD;
               6. Require oxygen therapy due to COVID-19&#xD;
&#xD;
               7. Require an increase in baseline oxygen flow rate due to COVID-19 in those on&#xD;
                  chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.&#xD;
&#xD;
          2. Weighs &lt; 40 kg&#xD;
&#xD;
          3. History of vaccination against SARS-CoV2&#xD;
&#xD;
          4. History of convalescent plasma or IVIG therapy within 3 months of first SARS-CoV2&#xD;
             viral determination positive&#xD;
&#xD;
          5. History of previous SARS-CoV2 infection&#xD;
&#xD;
          6. History of participation in any clinical study involving an investigational&#xD;
             intervention within 30 days or 5 half-lives of the previous intervention, whichever is&#xD;
             longer.&#xD;
&#xD;
          7. Unable to achieve informed consent for any reason&#xD;
&#xD;
          8. Known Pregnancy&#xD;
&#xD;
          9. Actively breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fraser Health Authority</name>
      <address>
        <city>Fraser Health Region</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B-Epic Study</last_name>
      <phone>+1 236 332 9517</phone>
      <email>b-epicstudy@fraserhealth.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fraser Health</investigator_affiliation>
    <investigator_full_name>Gregory Haljan, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bamlanivimab</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>hospitalization</keyword>
  <keyword>mortality</keyword>
  <keyword>COVID-19</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

